title: A report from the 46th Annual Meeting of the European Association for the Study of Diabetes (September 20-24, 2010 - Stockholm, Sweden).
abstract: Old and modern architecture go hand in hand along the many waterfronts in Stockholm, just as old (established) and new (investigational) drugs for treating diabetes shared time and space at the oral and poster sessions during the 2010 European Association for the Study of Diabetes (EASD) meeting in Älfsjö. Old and new drugs shared the spotlight at the meeting, the main declared objective of which was to promote excellence in diabetes care through research and education. Although it is important to attend the EASD meeting in order to obtain information on what's new firsthand-new drugs, new indications, new treatment modalities... as well as news on negative aspects and limitations of drug therapy-not all healthcare professionals can attend so many annual meetings, and those who can, cannot attend many of the parallel sessions, and thus alternative sources of information are needed. Indeed, education has a major role in the management and prevention of diabetes, obesity and related disorders, all of which carry a high cardiovascular risk, but if educating patients and the general population is essential, so is informing healthcare professionals about new therapies and new findings related with the management of diabetes. In line with the previously stated attendance limitations and alternative sources of information-or education-this is the scope of the following report, which complements other information on subjects discussed during the EASD meeting in Stockholm available online through other channels.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D000818:Animals; D048909:Diabetes Complications / Q000628:therapy; D003920:Diabetes Mellitus / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D054795:Incretins / Q000819:agonists / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013548:Sweden; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D045162:Thiazolidinediones